Condition: Brain Tumor, Pediatric · Cancer-related Fatigue · Methylphenidate · Sponsor: Odense University Hospital
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking. The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD). If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
This description comes directly from the study's public registry record.
Sebastian W Most-Mottelson, MD, PhD Student · +45 21567257 · sebastian.wenzel.most-mottelson@rsyd.dk
Mathias Rathe, Consultant, MD, PhD · +45 20469682 · mathias.rathe@rsyd.dk
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Not Yet Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Odense University Hospital | Odense, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06905587